Macrogenics (FRA:M55) Non Operating Income: €-45.8 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
50 GF Score
Price €3.40
GF Value €3.12
! 6 Warning Signs
View Full Analysis

What is Macrogenics Non Operating Income?

Macrogenics FRA:M55 -2.86% 50 Non Operating Income is €-45.8 Mil as of Jun. 2026. GuruFocus rates FRA:M55 with a GF Score™ of 50/100 and a GF Value™ of €3.12. The stock has 6 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Macrogenics's Non Operating Income for the three months ended in Jun. 2026 was €-45.8 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was €-45.8 Mil.

Macrogenics Non Operating Income Related Terms

Macrogenics Non Operating Income Historical Data

* Premium members only.

The historical data trend for Macrogenics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Non Operating Income Chart

Macrogenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 1.57 138.40 34.62 0.00

Macrogenics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -45.80
FRA:M55
50GF Score
Macrogenics Inc FRA:M55
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €-45.8 Mil mean?
Macrogenics (FRA:M55) has a Non Operating Income of €-45.8 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Macrogenics and its competitors.
Is Macrogenics' Non Operating Income too high?
Macrogenics' current Non Operating Income is €-45.8 Mil. Overall, Macrogenics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Non Operating Income compare to WHWK and SRZN?
Macrogenics' Non Operating Income of €-45.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Macrogenics and its competitors. Macrogenics's current Non Operating Income is €-45.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current Non Operating Income of €-45.8 Mil. The stock's GF Value™ is €3.12, compared to a current price of €3.40 — trading 9% above its estimated fair value. The current Non Operating Income is €-45.8 Mil. Macrogenics' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Non Operating Income is €-45.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.40 is trading 9% above its estimated GF Value™ of €3.12.

Key valuation signals for FRA:M55:

  • Non Operating Income: €-45.8 Mil
  • GF Value™: €3.12 vs. price of €3.40 (9% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
50GF Score

Get the complete analysis for FRA:M55

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price
€3.12
GF Value